These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 36363529)

  • 21. Potential and unsolved problems of anti-PD-1/PD-L1 therapy combined with radiotherapy.
    Cao Y; Li W; Wang Z; Pang H
    Tumori; 2021 Aug; 107(4):282-291. PubMed ID: 32734832
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Role of Traditional Chinese Medicine in Cancer Immunotherapy: Current Status and Future Directions.
    Xie J; Huang H; Li X; Ouyang L; Wang L; Liu D; Wei X; Tan P; Tu P; Hu Z
    Am J Chin Med; 2023; 51(7):1627-1651. PubMed ID: 37638827
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enhanced B7-H4 expression in gliomas with low PD-L1 expression identifies super-cold tumors.
    Chen D; Li G; Ji C; Lu Q; Qi Y; Tang C; Xiong J; Hu J; Yasar FBA; Zhang Y; Hoon DSB; Yao Y; Zhou L
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32457124
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immune Checkpoint Blockade in Breast Cancer Therapy.
    Bu X; Yao Y; Li X
    Adv Exp Med Biol; 2017; 1026():383-402. PubMed ID: 29282694
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade.
    Li HY; McSharry M; Bullock B; Nguyen TT; Kwak J; Poczobutt JM; Sippel TR; Heasley LE; Weiser-Evans MC; Clambey ET; Nemenoff RA
    Cancer Immunol Res; 2017 Sep; 5(9):767-777. PubMed ID: 28819064
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immune checkpoint silencing using RNAi-incorporated nanoparticles enhances antitumor immunity and therapeutic efficacy compared with antibody-based approaches.
    Won JE; Byeon Y; Wi TI; Lee CM; Lee JH; Kang TH; Lee JW; Lee Y; Park YM; Han HD
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35228265
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
    Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immune checkpoint inhibition in ovarian cancer.
    Hamanishi J; Mandai M; Konishi I
    Int Immunol; 2016 Jul; 28(7):339-48. PubMed ID: 27055470
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Focus on immune checkpoint PD-1/PD-L1 pathway: New advances of polyphenol phytochemicals in tumor immunotherapy.
    Liu K; Sun Q; Liu Q; Li H; Zhang W; Sun C
    Biomed Pharmacother; 2022 Oct; 154():113618. PubMed ID: 36055113
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination cancer immunotherapy targeting TNFR2 and PD-1/PD-L1 signaling reduces immunosuppressive effects in the microenvironment of pancreatic tumors.
    Zhang X; Lao M; Xu J; Duan Y; Yang H; Li M; Ying H; He L; Sun K; Guo C; Chen W; Jiang H; Zhang X; Bai X; Liang T
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35260434
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of small-molecule immune checkpoint inhibitors of PD-1/PD-L1 as a new therapeutic strategy for tumour immunotherapy.
    Li K; Tian H
    J Drug Target; 2019 Mar; 27(3):244-256. PubMed ID: 29448849
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Extracellular vesicle-based checkpoint regulation and immune state in cancer.
    Mortezaee K; Majidpoor J
    Med Oncol; 2022 Sep; 39(12):225. PubMed ID: 36175741
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PD-1/PD-L1 immune checkpoints: Tumor vs atherosclerotic progression.
    Liang Y; Li L; Chen Y; Xiao J; Wei D
    Clin Chim Acta; 2021 Aug; 519():70-75. PubMed ID: 33872608
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Research Advances of Immunotherapy of Exosome PD-L1 
in Non-small Cell Lung Cancer].
    Wang N; Song X
    Zhongguo Fei Ai Za Zhi; 2022 Sep; 25(9):689-695. PubMed ID: 36172735
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of T-cell-mediated immune response via the PD-1/ PD-L1 axis in cholangiocarcinoma cells.
    Suriyo T; Fuangthong M; Artpradit C; Ungtrakul T; Sricharunrat T; Taha F; Satayavivad J
    Eur J Pharmacol; 2021 Apr; 897():173960. PubMed ID: 33617828
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer.
    Zhang H; Dai Z; Wu W; Wang Z; Zhang N; Zhang L; Zeng WJ; Liu Z; Cheng Q
    J Exp Clin Cancer Res; 2021 Jun; 40(1):184. PubMed ID: 34088360
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A mechanistic systems pharmacology modeling platform to investigate the effect of PD-L1 expression heterogeneity and dynamics on the efficacy of PD-1 and PD-L1 blocking antibodies in cancer.
    Bazzazi H; Shahraz A
    J Theor Biol; 2021 Aug; 522():110697. PubMed ID: 33794288
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PD-1/PD-L1 blockade in cancer treatment: perspectives and issues.
    Hamanishi J; Mandai M; Matsumura N; Abiko K; Baba T; Konishi I
    Int J Clin Oncol; 2016 Jun; 21(3):462-73. PubMed ID: 26899259
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel Small Molecule Inhibitors of Programmed Cell Death (PD)-1, and its Ligand, PD-L1 in Cancer Immunotherapy: A Review Update of Patent Literature.
    Kopalli SR; Kang TB; Lee KH; Koppula S
    Recent Pat Anticancer Drug Discov; 2019; 14(2):100-112. PubMed ID: 30370857
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond.
    Ai L; Xu A; Xu J
    Adv Exp Med Biol; 2020; 1248():33-59. PubMed ID: 32185706
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.